Dr Reddy’s

Dr Reddy's Laboratories has forayed into hormone replacement therapy segment by acquiring trademarks of specialty brands, Progynova and Cyclo-Progynova and related assets, for India from UK-headquartered Mercury Pharma Group for USD 32.15 million, according to a company statement. Progynova (estradiol valerate) is an oral hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms and for the prevention of postmenopausal osteoporosis. Cyclo-Progynova (estradiol valerate and norgestrel) is a combined hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms, providing both estrogen and progestogen components. As per IQVIA MAT December 2025, the brand recorded sales of Rs 100 crore. The acquisition strengthens Dr Reddy's gynaecology portfolio and marks a strategic entry into the hormone replacement therapy segment, the drug firm stated. "The acquisition will serve as the spearhead of our expansion into the HRT segment, ...

The company ​last month received an approval from ‌India's drug regulator ​to manufacture ‌and sell the generic version ‌of blockbuster diabetes drug Ozempic

Ozempic is also used off-label for weight loss due to its appetite-suppressing effects

Strong domestic demand is set to lift pharma revenues by up to 11% in Q3FY26, though pressure from generic Revlimid in the US may limit profit growth

The company said Hevaxin is the only hepatitis E vaccine approved by the Drug Controller General of India (DCGI) and is indicated for active immunisation against HEV infection

According to the agreement, Immutep will receive from Dr Reddy's an upfront payment of $20 million (around AUD 30.2 million)

Over the last few years, Dr Reddy's has diversified its portfolio beyond generics to include cancer therapies as it battles pricing pressures in North America, its largest market

The European Commission's approval allows Dr Reddy's to market AVT03 across the European Union and European Economic Area for treating conditions that cause bone weakening

Indian cos like Biocon, DRL, Intas, Lupin stand to benefit from the proposed move

Health Canada's non-compliance notice may delay DRL's semaglutide generic launch by 8-12 months, say analysts; shares fall over 4 per cent on Thursday

Drugmaker Dr Reddy's Laboratories Ltd on Tuesday said it has received establishment inspection report from the US health regulator for its formulations manufacturing facility at Srikakulam in Andhra Pradesh, classifying the facility as voluntary action indicated. The US Food & Drug Administration (USFDA) had conducted a GMP and a Pre-Approval Inspection (PAI) conducted by at the company's formulations manufacturing facility FTO 11 in Srikakulam, Andhra Pradesh, India, intimated to the exchanges on July 18, 2025, Dr Reddy's Laboratories Ltd said in a regulatory filing. "We wish to inform you that the company has received the Establishment Inspection Report (EIR) on October 20, 2025. The USFDA has classified the inspection outcome as 'Voluntary Action Indicated (VAI)'," it said, adding the inspection is officially closed. Under voluntary action indicated (VAI), while objectionable conditions were found and documented during an inspection, the agency is not prepared to take or ...

Tegoprazan, a next-generation acid blocker, offers faster relief and lasting control for GERD, NERD, and gastric ulcers, addressing India's rising acid peptic disease burden

Despite missing Q1 expectations, Dr Reddy's continues to see growth in key markets like Europe and India, while managing costs to offset challenges in the US

The company initially plans to launch the generic version in Canada, India, Brazil, Turkey and other emerging markets, subject to patent expiry, Israeli said at a press conference

Delhi High Court bars Dr Reddy's and OneSource from selling semaglutide in India, supporting Novo Nordisk's patent rights as it fast-tracks Wegovy launch amid growing obesity drug demand

At 6:50 AM, GIFT Nifty futures were trading 496 points higher at 24,561.5, indicating a gap-up start for the bourses.

Dr Reddy's posts highest-ever quarterly revenue and profit in Q4 FY25 with strong growth in generics, PSAI and NRT acquisition; FY25 PAT up 2 per cent at ₹5,654 crore

Q4 FY25 company results today: Birla Corporation and MapmyIndia will be among 69 companies to post earnings reports for the January-March quarter on May 9

Dr Reddy's Labs Q4 results 2025 date: Dr Reddy's Laboratories is scheduled to announce its fourth quarter (Q4FY25) results on Friday, May 9, 2025

There are 21,757 permanent employees on company rolls as on March 31, 2024; cost optimisation to offset margin pressure due to declining Revlimid sales